About Actag
Founded to solve a fundamental problem in genomic data governance.
Our Mission
Actag exists to make genomic data safe, secure, and accessible — for science and for the individuals whose DNA it represents. We build the infrastructure that allows genetic information to fulfill its potential in medicine and research without compromising the privacy or autonomy of the people it describes.
Our platform serves three constituencies simultaneously: the research institutions that generate genomic data, the clinical systems that act on it, and the individuals whose identities it encodes. Each group has distinct requirements; we believe a single, well-governed platform can meet all of them.
The Name
ACTAG derives from the four nucleotide bases of DNA: adenine (A), cytosine (C), thymine (T), and guanine (G). These four bases are the fundamental units of the genetic code — the alphabet from which all biological information is written. The name reflects the company's focus on the building blocks of human genetics and our commitment to operating at that foundational level.
In the wordmark, each letter carries a color association drawn from the DNA base palette: A in sage green, C in navy, T in deep rose, and G in amber gold — a subtle visual reference to the four-base structure of the genome.
Market Context
The intersection of blockchain technology and genomic data governance has grown from a theoretical proposition to a field of operational practice. A systematic review of 255 academic papers spanning 2009–2026 documents a 17-fold increase in annual publication rate between the 2023–2026 period and the prior baseline — a pace consistent with rapid field maturation rather than speculative interest.
The addressable market for blockchain-enabled genomic data platforms is estimated to grow from $524 million to $20 billion over the coming decade, driven by the convergence of large-scale sequencing programs, pharmacogenomics adoption in clinical care, and increasing regulatory attention to genomic privacy. Sixty percent of recent technical implementations use hybrid on-chain/off-chain architectures — the design approach Actag has adopted.
Privacy-preserving cryptographic methods — including zero-knowledge proofs and homomorphic encryption — have transitioned from theoretical constructs to operationally viable tools. The infrastructure moment for genomic data governance has arrived.
Founding
Actag was founded in 2026 by a geneticist and a law professor who recognized that the world's most sensitive data — the human genome — lacked adequate infrastructure for storage, access, and governance.
Talia Oranburg, PhD, brings expertise in large-scale computational genomics and population-level data analysis. Seth C. Oranburg, JD, brings expertise in blockchain regulation, data privacy law, and corporate governance, with experience at leading Silicon Valley and New York law firms. Together, they combine the scientific and legal perspectives required to build a platform that is both technically sound and regulatorily defensible.
The company is headquartered in New Hampshire and is relocating to Washington, D.C. in 2026, positioning it at the center of federal regulatory activity in health data policy.